April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.
Health care providers often believe stereotypes that PWID are irresponsible and won't adhere to PrEP, according to data presented at the 2019 National HIV Prevention Conference.
Although people living with HIV who "party and play" appear more likely to struggle with treatment adherence, new research suggests that concern does not apply to PrEP.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
High HIV prevalence among black MSM on PrEP; substance use reduction lessens depressive symptoms; correlations between pain symptoms and age; the impact of seroconversion and antiretroviral therapy on risk behaviors.
Sexual risk behavior increased significantly among men who have sex with men when they started using meth, reports a study published recently.
This is the first major study to find that a once-a-day antiretroviral taken by HIV-negative injection drug users can have the same benefits as when pre-exposure prophylaxis (PrEP) is taken to prevent sexual HIV transmission.
Oral PrEP is a critically important HIV prevention tool that can play a significant role in reducing individual infection risk and helping to end the epidemic. Today's news, that PrEP prevents HIV among people whose primary infection risk is injectio...
Daily oral PrEP (pre-exposure prophylaxis) with a tablet containing tenofovir disoproxil fumarate (tenofovir, marketed in the United States under the brand name Viread®) was found to reduce the risk of acquiring HIV by approximately 49 perce...